Issued on: 15/04/2026 - 14:53

Revolution Medicines' experimental oral drug ⁠helped patients ​with pancreatic cancer live longer and showed an improvement in survival without worsening ​of the disease in a keenly anticipated late-stage trial. Patients who received the once-daily pill, daraxonrasib, showed a median overall survival of 13.2 months compared with 6.7 months ​for ‌those who were given intravenous cytotoxic chemotherapy, the standard ⁠of care, the company said on Monday.

Elon Musk's SpaceX aborts booster recovery due to technical issues

Youth Olympic Games organisers hail Senegal's capability to host major events

France and Cambodia share their love for pétanque in Phnom Penh

Washington divided over how to deal with fallout from the Nvidia case

US: What exactly caused the longest nationwide ground stop in 25 years?

US Transport Secretary asks Congress for $30 bn to upgrade aviation infrastructure

USA: All passengers survive after tanker hits docked river cruise ship in New Orleans

Inside Ethiopia's war: Rare access to a hospital treating victims of renewed fighting

Who are the 'street medics' showing up at protests around the world?

U2 releases first new studio album in a decade, 'Caranaval de Luz'

The content you requested does not exist or is not available anymore.